海南葫芦娃药业集团股份有限公司 2024 年度股东大会 会议资料 2025 年 5 月 | | | | 2024 | 年度股东大会会议议程 2 | | | --- | --- | --- | | 2024 | 年度股东大会会议须知 4 | | | 议案一: | 关于公司 年度董事会工作报告的议案 5 | 2024 | | 议案二: | 关于公司 年度监事会工作报告的议案 12 | 2024 | | 议案三: | 关于公司 年度报告及其摘要的议案 15 | 2024 | | 议案四: | 关于公司 年度财务决算报告的议案 16 | 2024 | | 议案五: | 关于 2024 年度拟不进行利润分配的议案 20 | | | 议案六: | 关于确认董事 2024 年度薪酬及 2025 年度薪酬方案的议案 21 | | | 议案七: | 关于确认监事 2024 年度薪酬及 2025 年度薪酬方案的议案 22 | | | 议案八: | 关于公司向金融机构申请 2025 年度综合授信额度及融资租赁、保理暨 | | | | 提供相应担保额度预计的议案 23 | | | 2024 | 年度独立董事述职报告（刘秋云） 28 ...

Core Insights - The company reported a significant decline in revenue and increased losses for the year 2024, indicating challenges in its business operations [1][2] Financial Performance - The company achieved a revenue of 1.414 billion yuan in 2024, a year-on-year decrease of 21.26% [1] - The net loss attributable to shareholders was 274 million yuan, an increase of 2629.23% year-on-year [1] - The adjusted net loss was 325 million yuan, expanding by 2250% compared to the previous year [1] - Basic earnings per share were -0.69 yuan, and the weighted average return on equity dropped to -31.66% [1] Revenue Breakdown - Revenue from respiratory system drugs was 989 million yuan, down 10.17% year-on-year, accounting for 70% of total revenue [2] - Revenue from digestive system drugs plummeted by 56.94% to 146 million yuan [2] - The company launched a new nutritional supplement, the compound lysine granules, and has received approval for seven health product varieties [2] R&D and Investment - R&D expenses increased by 58.63% year-on-year to 250 million yuan, representing 17.65% of total revenue [2] - The company added 12 new drug approvals and has seven Class I traditional Chinese medicine innovations in clinical stages, with three in Phase III trials [2] - The company is focusing on child-friendly formulations, including nebulized inhalation solutions and oral dissolving films [2] Asset and Financial Management - Fixed assets surged by 192.28% to 1.124 billion yuan, attributed to the launch of the Meian Children's Medicine intelligent manufacturing base [2] - Construction in progress decreased by 71.05% to 253 million yuan [2] - Cash and cash equivalents fell by 51.35% to 254 million yuan, indicating pressure on accounts receivable turnover [2] - Financial expenses increased by 74.36% due to the capitalization of interest expenses after project completion [2]

Core Insights - A-share listed companies demonstrated strong resilience in 2024, with total operating revenue reaching 62.33 trillion yuan, a year-on-year increase of 0.57%, and net profit attributable to shareholders of 5.06 trillion yuan, up 1.05% [1][2] - The growth was primarily driven by advancements in artificial intelligence (AI) technology, which significantly boosted demand in sectors such as GPU, PCB, and storage chips [2][3] - Despite overall growth, non-financial companies faced challenges, with a slight decline in revenue and a notable drop in net profit [1][3] Financial Performance - Among the 5402 listed companies, 4029 reported positive earnings, with 548 companies achieving over 100% growth in net profit [2] - The chemical company Zhengdan achieved a remarkable 119-fold increase in net profit, driven by soaring TMA prices due to supply-demand imbalances [2][3] - The semiconductor sector saw significant profit increases, with companies like Zhaoyi Innovation and Weir Shares reporting net profit growth of 584.21% and 498.11%, respectively [3] Sector Analysis - The AI sector is identified as a key growth driver, with companies in the GPU, PCB, and optical module industries experiencing substantial performance improvements [2][3] - The consumer electronics market is also rebounding, with a reported 5.6% year-on-year increase in smartphone shipments in China [3][4] International Expansion - A total of 3653 listed companies reported overseas revenue of 9.43 trillion yuan, accounting for approximately 20% of their total revenue [6][7] - Companies like Luxshare Precision and BYD achieved over 100 billion yuan in overseas revenue, with notable growth in emerging markets [6][7] - The internationalization strategies include local market investments and partnerships, particularly in Africa and the Middle East [7][8] Challenges and Losses - Despite overall positive performance, 124 companies reported net losses exceeding 1 billion yuan, with the real estate sector being particularly affected [9][10] - Vanke A led the loss rankings with a staggering 494.78 billion yuan loss, highlighting the difficulties faced in the real estate market [9][10] - The energy sector, including solar and lithium companies, also reported significant losses due to overcapacity and intensified competition [10] Regulatory Environment - The introduction of stricter delisting regulations is expected to normalize the delisting process, with 52 companies delisted in 2024 [11][12] - New rules include higher thresholds for financial delisting criteria, aiming to enhance market stability and protect investor interests [11][12]

Core Viewpoint - The company HuLuWa (605199.SH) has reported significant financial issues, including major internal control deficiencies, leading to a substantial decline in revenue and profits for 2024 [1][2][7]. Financial Performance - In 2024, HuLuWa achieved revenue of 1.414 billion yuan, a year-on-year decrease of 21.26% [4]. - The net profit attributable to shareholders was a loss of 274 million yuan, a year-on-year decline of 2629.23% [4]. - The net profit after deducting non-recurring items was a loss of 325 million yuan, down 2250.82% year-on-year [4]. - Cumulatively, the losses for 2023 and 2024 reached approximately 339 million yuan [4]. Product Performance - Among the top ten products, only the sales volume of Qiangli Pipa Lu increased, while the other nine products experienced a decline in sales [5]. - Notably, sales volumes for key products such as Changyanning Capsules and Compound Cold Medicine Granules dropped significantly, with reductions of 59.1% and 44.1% respectively [5]. Internal Control Issues - The auditing firm issued a negative opinion on HuLuWa's internal control audit report, indicating significant deficiencies [6][8]. - The company faced administrative regulatory measures from the Hainan Securities Regulatory Bureau due to inaccuracies in financial disclosures [2][7]. - The internal control deficiencies were linked to improper approval processes for significant transactions, raising concerns about the company's financial reporting integrity [8]. Stock Market Impact - Following the negative audit report, HuLuWa's stock will be subject to risk warnings, changing its trading name to "ST HuLuWa" starting April 30 [2][8]. - As of April 28, the stock closed at 13.06 yuan per share, with a total market capitalization of 5.225 billion yuan [8].

Core Viewpoint - Hainan Huhuwawa Pharmaceutical Group Co., Ltd. faces significant internal control issues, leading to a negative audit opinion and a stock trading suspension, with a change in stock abbreviation to "ST Huhuwawa" starting April 30, 2025 [1][3][5] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.414 billion yuan, a year-on-year decrease of 21.26%, and a net profit attributable to shareholders of -274 million yuan, a staggering decline of 2629.23% [10] - In the first quarter of 2025, the company achieved a revenue of 337 million yuan, down 28.42% year-on-year, with a net profit of approximately 24.35 million yuan, a decrease of 11.23% [10] Internal Control Issues - The audit report from Lixin Certified Public Accountants highlighted three major areas of concern regarding internal controls, including the lack of complete financial data related to restated financial statements and issues with accounts receivable from key clients [3][5] - The company has been criticized for significant deficiencies in its internal control over financial reporting, resulting in a negative opinion from the auditors [5] Management Changes - The company's general manager, Zhang Mingrui, resigned for personal reasons less than two months after taking office, marking a period of instability in leadership [2][6] - This resignation follows the earlier departure of Liu Jingping from the general manager position, who remains as chairman and has been a key figure in the company since its inception [7][8] Related Transactions - In 2024, the company purchased eight R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for 42.0537 million yuan, raising concerns due to familial ties between the company's actual controller and the legal representative of the vendor [4]

距离年报正式披露仅剩5个交易日时，葫芦娃发布了预亏公告，已构成违规，而这才是开始。 2025年3月14日，葫芦娃公告称，收到海南证监局出具的《行政监管措施决定书》（简称《决定 书》）。海南证监局表示，在现场检查中发现葫芦娃2023年年度报告中营业收入、利润等财务信息披露 不准确，公司已违反了《上市公司信息披露管理办法》。海南证监局对葫芦娃采取责令改正的行政监管 措施，并将相关违规行为记入资本市场诚信档案数据库。 当时，距离立信会计师事务所接手葫芦娃2024年年报审计工作仅过去4个月，而履历丰富的新总经理张 铭芮走马上任才10天时间。根据之前公告，张铭芮曾在重庆太极实业（集团）股份有限公司担任副总经 理职务，又在津药达仁堂集团股份有限公司担任过党委书记、董事长职务。 在《决定书》下发之前，葫芦娃算出来的2024年年度业绩或许不是目前披露的数据。按照规定，如果上 市公司预计其年度经营业绩将出现净利润为负值、净利润与上年同期相比上升或下降超过50%、实现扭 亏为盈、期末净资产为负值等情形的，应在不晚于1月31日披露年度业绩预告。 4月29日，葫芦娃（605199.SH）停牌一天，自4月30日开市起，股票复牌并实施其 ...

Summary of Key Points Core Viewpoints - The report highlights the ongoing trend of stock suspensions due to delisting risk warnings across multiple companies, indicating a potential downturn in market confidence and stability [2][3][4]. Company Listings - Several companies are scheduled for initial public offerings (IPOs) on April 29, 2025, including Tai Li Technology (301595) and Ze Run New Energy (301636), which may attract investor interest [1]. - The report notes the specific dates for various IPO-related activities, such as inquiry periods and fund unfreezing dates, which are crucial for market participants [1]. Stock Suspension Announcements - Numerous companies, including Guohua Network Security (000004) and Nanhua Biology (000504), have announced stock suspensions due to delisting risk warnings, reflecting a significant concern regarding their financial health [2][3]. - The report lists a total of 30 companies facing stock suspensions on April 29, 2025, due to various risk warnings, which may impact investor sentiment and trading volumes [2][3][4]. Special Suspensions - Companies like *ST Xu Lan (000040) and *ST Gong Zhi (000584) are highlighted for potential termination of listings, indicating severe financial distress and regulatory scrutiny [4][5]. - The report emphasizes the importance of monitoring these companies as their situations evolve, which could present both risks and opportunities for investors [4][5].

证券代码：605199 证券简称：葫芦娃 公告编号：2025-026 海南葫芦娃药业集团股份有限公司 关于前期会计差错更正的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次前期会计差错更正是根据中国证券监督管理委员会海南监管局下发的 《行政监管措施决定书》（〔2025〕7 号），追溯调整已披露的 2023 年年度报告和 2024 年半年度报告、2024 年第一季度、2024 年第三季度报告的财务数据。 ●本次对前期会计差错采用追溯重述法进行更正，相对应的公司 2023 年年度、 2024 年半年度财务报表及附注、2024 年第一季度、2024 年第三季度报告进行调整。 影响公司合并资产负债表、利润表，母公司资产负债表、利润表。 本次前期会计差错更正已经公司董事会、监事会审议通过，无需提交股东大 会审议。 一、概述 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于2025年4月27日召开 了第三届董事会第五次会议、第三届监事会第五次会议审议通过了《关于前期会计 差错更正的议案》，同意按照《企业会计 ...

经中国证券监督管理委员会证监许可〔2020〕1086号文核准，公司向社会公 众公开发行人民币普通股（A股）股票4,010万股，发行价格为每股人民币5.19元， 募集资金总额为20,811.90万元，扣除各项发行费用5,707.93万元后的募集资金净 额为15,103.97万元。上述募集资金到位情况业经天健会计师事务所（特殊普通合 伙）审验并出具《验资报告》（天健验〔2020〕246号）。 （二）募集资金使用和结余情况 截至2024年12月31日，公司募集资金使用和结存情况如下： | 项目 | 金额（元） | | --- | --- | | 募集资金总额 | 208,119,000.00 | | 减：承销佣金及其他发行费用 | 57,079,347.77 | | 募集资金净额 | 151,039,652.23 | | 减：以募集资金置换预先投入自筹资金的金额（注） | 13,914,870.00 | | 减：以前年度募集资金直接投入募投项目金额 | 101,915,644.18 | | 加：以前年度累计利息收入扣除手续费金额 | 541,090.35 | | 募集资金年初余额 | 35,750,228.40 | ...

海南葫芦娃药业集团股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》和《海南葫芦娃药业集团股份有限 公司章程》《海南葫芦娃药业集团股份有限公司审计委员会工作细则》等规定和要求， 董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。2024 年，公司聘请的财 务审计机构和内部控制审计机构为立信会计师事务所（特殊普通合伙）（以下简称"立 信"）。现将董事会审计委员会对会计师事务所 2024 年度履行监督职责的情况汇报如 下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年在上海 创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会计师事务所， 注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网络 BDO 的成员所，长 期从事证券服务业务，新证券法实施前具有证券、期货业务许可证，具有 H 股审计资格， 并已向美国公众公司会计监督委员会（ ...